DP
LVTX

Diadema Partners’s LAVA Therapeutics LVTX Stock Holding History

Diadema Partners’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21,508
Closed -$20.5K – 138
2024
Q4 		$20.5K Buy
+21,508
New +$33.8K 0.01% 102

Other funds holding LVTX

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
PFA
Pathway Financial Advisors South Burlington, Vermont $857M AUM 17.21% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Diadema Partners's LVTX Position: Q1 2025 in Review

Diadema Partners sold out of LAVA Therapeutics (LVTX) in Q1 2025, closing a stake of 21,508 shares — an estimated $20.5K sold.

Diadema Partners first reported a position in LVTX in Q4 2024 and held it in 1 quarter. The position peaked at $20.5K in Q4 2024. 20 funds tracked by Wall St. Rank hold LVTX as of Q1 2025.

  • Diadema Partners reported no remaining LAVA Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Diadema Partners sold 21,508 LAVA Therapeutics shares in Q1 2025, an estimated $20.5K.
  • Diadema Partners first reported a position in LAVA Therapeutics in Q4 2024 and held it in 1 quarter.
  • Diadema Partners's LAVA Therapeutics position peaked at $20.5K in Q4 2024.
  • 20 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q1 2025.

Based on Diadema Partners's 13F filing for Q1 2025, filed 15 May 2025.